BIOMAT Database Logo BIOMAT Database Logo

Safety and pharmacokinetics of escalating daily doses of the antituberculosis drug rifapentine in healthy volunteers. 2012

K E Dooley, and E E Bliven-Sizemore, and M Weiner, and Y Lu, and E L Nuermberger, and W C Hubbard, and E J Fuchs, and M T Melia, and W J Burman, and S E Dorman
Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. kdooley1@jhmi.edu

Rifapentine (RP T) is an antituberculosis drug that may shorten treatment duration when substituted for rifampin (RI F).The maximal tolerated daily dose of RP T and its potential for cytochrome 3A4 induction and autoinduction at clinically relevant doses are unknown. In this phase I, dose-escalation study among healthy volunteers, daily doses as high asa prespecified maximum of 20 mg/kg/day were well tolerated. Steady-state RP T concentrations increased with dose from 5 to 15 mg/kg, but area under the plasma concentration–time curve (AU C0–24) and maximum concentration (Cmax)were similar in the 15- and 20-mg/kg cohorts. Although RP T pharmacokinetics (PK) appeared to be time-dependent,accumulation occurred with daily dosing. The mean AU C0–12 of oral midazolam (MDZ), a cytochrome 3A (CYP 3A) probe drug, was reduced by 93% with the coadministration of RPT and by 74% with the coadministration of RIF (P < 0.01).Changes in the oral clearance of MDZ did not vary by RP T dose. In conclusion, RP T was tolerated at doses as high as20 mg/kg/day, its PK were less than dose-proportional, and its CYP 3A induction was robust.

UI MeSH Term Description Entries
D008297 Male Males
D008874 Midazolam A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH. Dormicum,Midazolam Hydrochloride,Midazolam Maleate,Ro 21-3981,Versed,Hydrochloride, Midazolam,Maleate, Midazolam,Ro 21 3981,Ro 213981
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000995 Antitubercular Agents Drugs used in the treatment of tuberculosis. They are divided into two main classes: "first-line" agents, those with the greatest efficacy and acceptable degrees of toxicity used successfully in the great majority of cases; and "second-line" drugs used in drug-resistant cases or those in which some other patient-related condition has compromised the effectiveness of primary therapy. Anti-Tuberculosis Agent,Anti-Tuberculosis Agents,Anti-Tuberculosis Drug,Anti-Tuberculosis Drugs,Antitubercular Agent,Antitubercular Drug,Tuberculostatic Agent,Tuberculostatic Agents,Antitubercular Drugs,Agent, Anti-Tuberculosis,Agent, Antitubercular,Agent, Tuberculostatic,Anti Tuberculosis Agent,Anti Tuberculosis Agents,Anti Tuberculosis Drug,Anti Tuberculosis Drugs,Drug, Anti-Tuberculosis,Drug, Antitubercular
D012293 Rifampin A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160) Rifampicin,Benemycin,Rifadin,Rimactan,Rimactane,Tubocin
D051544 Cytochrome P-450 CYP3A A cytochrome P-450 suptype that has specificity for a broad variety of lipophilic compounds, including STEROIDS; FATTY ACIDS; and XENOBIOTICS. This enzyme has clinical significance due to its ability to metabolize a diverse array of clinically important drugs such as CYCLOSPORINE; VERAPAMIL; and MIDAZOLAM. This enzyme also catalyzes the N-demethylation of ERYTHROMYCIN. CYP3A,CYP3A4,CYP3A5,Cytochrome P-450 CYP3A4,Cytochrome P-450 CYP3A5,Cytochrome P-450IIIA,Cytochrome P450 3A,Cytochrome P450 3A4,Cytochrome P450 3A5,Erythromycin N-Demethylase,Taurochenodeoxycholate 6-alpha-Monooxygenase,3A5, Cytochrome P450,6-alpha-Monooxygenase, Taurochenodeoxycholate,Cytochrome P 450 CYP3A,Cytochrome P 450 CYP3A4,Cytochrome P 450 CYP3A5,Cytochrome P 450IIIA,Erythromycin N Demethylase,N-Demethylase, Erythromycin,P-450 CYP3A, Cytochrome,P-450 CYP3A4, Cytochrome,P-450 CYP3A5, Cytochrome,P-450IIIA, Cytochrome,P450 3A, Cytochrome,P450 3A5, Cytochrome,Taurochenodeoxycholate 6 alpha Monooxygenase
D019540 Area Under Curve A statistical means of summarizing information from a series of measurements on one individual. It is frequently used in clinical pharmacology where the AUC from serum levels can be interpreted as the total uptake of whatever has been administered. As a plot of the concentration of a drug against time, after a single dose of medicine, producing a standard shape curve, it is a means of comparing the bioavailability of the same drug made by different companies. (From Winslade, Dictionary of Clinical Research, 1992) AUC,Area Under Curves,Curve, Area Under,Curves, Area Under,Under Curve, Area,Under Curves, Area

Related Publications

K E Dooley, and E E Bliven-Sizemore, and M Weiner, and Y Lu, and E L Nuermberger, and W C Hubbard, and E J Fuchs, and M T Melia, and W J Burman, and S E Dorman
Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects.
April 2003, Antimicrobial agents and chemotherapy,
K E Dooley, and E E Bliven-Sizemore, and M Weiner, and Y Lu, and E L Nuermberger, and W C Hubbard, and E J Fuchs, and M T Melia, and W J Burman, and S E Dorman
Pharmacokinetics of escalating doses of intravenous repinotan in healthy male volunteers.
January 2005, Clinical drug investigation,
K E Dooley, and E E Bliven-Sizemore, and M Weiner, and Y Lu, and E L Nuermberger, and W C Hubbard, and E J Fuchs, and M T Melia, and W J Burman, and S E Dorman
Safety, Pharmacokinetics and Pharmacodynamics of Multiple Escalating Doses of PEGylated Exenatide (PB-119) in Healthy Volunteers.
March 2021, European journal of drug metabolism and pharmacokinetics,
K E Dooley, and E E Bliven-Sizemore, and M Weiner, and Y Lu, and E L Nuermberger, and W C Hubbard, and E J Fuchs, and M T Melia, and W J Burman, and S E Dorman
Safety and pharmacokinetics of multiple doses of aclidinium bromide administered twice daily in healthy volunteers.
April 2012, Pulmonary pharmacology & therapeutics,
K E Dooley, and E E Bliven-Sizemore, and M Weiner, and Y Lu, and E L Nuermberger, and W C Hubbard, and E J Fuchs, and M T Melia, and W J Burman, and S E Dorman
Pharmacokinetics of moxonidine after single and repeated daily doses in healthy volunteers.
December 1987, Journal of clinical pharmacology,
K E Dooley, and E E Bliven-Sizemore, and M Weiner, and Y Lu, and E L Nuermberger, and W C Hubbard, and E J Fuchs, and M T Melia, and W J Burman, and S E Dorman
Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects.
October 2002, Journal of clinical pharmacology,
K E Dooley, and E E Bliven-Sizemore, and M Weiner, and Y Lu, and E L Nuermberger, and W C Hubbard, and E J Fuchs, and M T Melia, and W J Burman, and S E Dorman
Novel dosing strategies increase exposures of the potent antituberculosis drug rifapentine but are poorly tolerated in healthy volunteers.
January 2015, Antimicrobial agents and chemotherapy,
K E Dooley, and E E Bliven-Sizemore, and M Weiner, and Y Lu, and E L Nuermberger, and W C Hubbard, and E J Fuchs, and M T Melia, and W J Burman, and S E Dorman
Safety and pharmacokinetics of multiple doses of intravenous ofloxacin in healthy volunteers.
February 1992, Antimicrobial agents and chemotherapy,
K E Dooley, and E E Bliven-Sizemore, and M Weiner, and Y Lu, and E L Nuermberger, and W C Hubbard, and E J Fuchs, and M T Melia, and W J Burman, and S E Dorman
Pharmacokinetics and safety of single rising doses of ofloxacin in healthy volunteers.
January 1992, Pharmacotherapy,
K E Dooley, and E E Bliven-Sizemore, and M Weiner, and Y Lu, and E L Nuermberger, and W C Hubbard, and E J Fuchs, and M T Melia, and W J Burman, and S E Dorman
Pharmacokinetics and safety of sitafloxacin after single oral doses in healthy volunteers.
December 2014, International journal of clinical pharmacology and therapeutics,
Copied contents to your clipboard!